Nara Healthspan Plan
Nara’s plan
Saved 1/15/2026
- Mixed breed
- female · intact
- 18.5 kg
- Ideal body condition
Current focus
Keep the lean foundation. Build more strength and resilience around it.
Nara is lean, active and free of recorded clinical concerns. Her clearest opportunities are a broader movement mix, a slightly more protein-forward diet, and making recovery around unfamiliar dogs easier to measure and improve.
Why now
Most structured exercise is still flat walking and fetch, while strength work, movement variety and recovery around close dog encounters are less developed.
Protect alongside itKeep Nara lean and energetic while adding strength, maintaining muscle and preserving confidence in everyday environments.
Signals already supporting the plan
- Body condition is 5/9, near the centre of the ideal range.
- Daily movement is already consistent at roughly 45–90 minutes.
- No pain, stiffness, digestive symptoms or chronic diagnosis were recorded.
- Daily calorie intake is already close to Nara's estimated maintenance range.
Energy
Nara’s maintenance estimate
Nara’s estimate is 850 to 1,000 kcal per day. About 875 kcal/day
The recorded day sits inside Nara's estimated maintenance range, so this Baseline does not support cutting calories simply for the sake of eating less. Keep the total broadly stable and use weight and body-condition trend to refine it.
This is an informed starting range, not a metabolic measurement; repeated weight and body-condition observations are what make it personal over time.
How Nara estimated this
Estimated maintenance 850–1,000 kcal/day
18.5 kg current weight, body condition 5/9, young-adult age, intact status and 45–90 minutes of daily movement.
Plan sequence
One clear start. Supporting moves behind it.
Work through the priorities in order. The reasoning stays available, while the next move remains obvious.
The first move
Broaden the movement mix
Add two controlled hill or varied-surface sessions and two short strength-focused play sessions most weeks.
Why this comes first
Nara already moves every day, but most structured activity is repetitive flat walking and frequent fetch.
Keeping movement varied gives strength, coordination and comfortable function more reason to stay robust as she ages.
Reasoned from this dog's record
Make the diet a little more protein-forward
Keep total calories around the current level, but favour a somewhat higher protein density and trim some carbohydrate allocation rather than simply feeding less.
Why this matters
The quantified foods provide at least 70 g protein per day, while carbohydrate by difference is about 59 g. For a lean, active dog, Nara would prefer the next diet change to improve the mix rather than reduce total energy.
Adequate protein and preserved lean mass become increasingly important with age; the useful question is composition within an appropriate calorie total.
Reasoned from this dog's record
Turn unfamiliar-dog recovery into a measurable plan
Work below Nara's reaction threshold, pair calm sightings with something she values, avoid forced greetings and record how long she takes to settle after close encounters.
Why this matters
She is relaxed at home and has no separation distress, but close unfamiliar dogs are a recurring trigger and recovery can take several minutes.
Emotional wellbeing is part of healthspan: reducing avoidable stress can make everyday movement, social exposure and owner routines easier to sustain.
Reasoned from this dog's record
The daily foundation
Nutrition decisions
The practical decision leads. Tap a figure for its context; calculations and provenance remain underneath.
The diet decision
Keep calories broadly stable; shift the mix a little more toward protein and a little less toward carbohydrate.
The total energy picture already looks sensible for Nara's current body condition. The more useful nutrition move is to improve protein density modestly while keeping the overall calorie budget similar and preserving the diet's completeness and balance.
Nutrition decisions
Tap for context
Calories875kcal/dayAbout
This includes the weighed dry food, wet food, topper, daily training treats and the weekly dental chews averaged across seven days.
Protein70g/dayAt least
The quantified foods provide about 70 g protein per day. Because the treat macros are not recorded, this is a lower bound rather than a claim about the exact whole-day total.
Fat37g/dayAt least
The quantified foods provide about 37 g fat per day. Treat fat is unknown, so Nara keeps the full-day figure as a minimum.
Carbohydrate59g/dayEstimated
For the three foods with complete guaranteed-analysis fields, carbohydrate is calculated by difference: 100 minus protein, fat, fibre, moisture and ash. Treat carbohydrate is not included because those label fields are not recorded.
Largest uncertaintyThe largest remaining nutrition uncertainty is the macro composition of roughly 80 kcal/day of treats.
See the full nutrition breakdown
Nara's recorded day is about 875 kcal. The three foods with usable composition data provide at least 70 g protein and 37 g fat, while about 59 g carbohydrate is calculated by difference. Treat calories are counted in the daily total, but their unrecorded macros are not guessed.
- Recorded energy
- ≈875 kcal/day
- Protein from quantified foods
- ≥70 g/day
- Fat from quantified foods
- ≥37 g/day
- Carbohydrate by difference
- ≈59 g/day
Calories
About 875 kcal/day
This includes the weighed dry food, wet food, topper, daily training treats and the weekly dental chews averaged across seven days.
Protein
At least 70 g/day
The quantified foods provide about 70 g protein per day. Because the treat macros are not recorded, this is a lower bound rather than a claim about the exact whole-day total.
Fat
At least 37 g/day
The quantified foods provide about 37 g fat per day. Treat fat is unknown, so Nara keeps the full-day figure as a minimum.
Carbohydrate
Estimated 59 g/day
For the three foods with complete guaranteed-analysis fields, carbohydrate is calculated by difference: 100 minus protein, fat, fibre, moisture and ash. Treat carbohydrate is not included because those label fields are not recorded.
Fibre
About 10 g/day
This is the crude fibre contributed by the three quantified foods. It is kept separate from digestible carbohydrate.
See what each food and extra contributes
Chicken & fish adult kibble
180 g · ≈671 kcal per day · ≈57.6 g protein per day
32% crude protein · 16% crude fat · 5% crude fibre · ≈29% carbohydrate by difference
Primary food; weighed daily.
Chicken & turkey wet food
100 g · ≈96 kcal per day · ≈10 g protein per day
10% crude protein · 8% crude fat · 1% crude fibre · ≈3.5% carbohydrate by difference
Supplemental wet food.
Cooked chicken & rice topper
17 g · ≈24 kcal per day · ≈2 g protein per day
12% protein · 3% fat · 1% fibre · ≈18% carbohydrate by difference
Small weighed topper.
Dried chicken training treats
8 pieces · ≈32 kcal per day
Calories recorded; macro label not recorded.
Dental chew
4 per week · ≈50 kcal/day averaged per day
Weekly intake averaged across seven days.
See what would make this more precise
- Treat calories are included in the energy total, while treat macros remain unknown rather than being estimated.
- Macro composition of the training treats and dental chew — Their calories are counted, but protein, fat and carbohydrate cannot be assigned without their label composition.
See sources and calculation notes
- Owner-recorded daily food weights and treat counts
- Recorded calorie densities and guaranteed analyses for the three foods
- Carbohydrate calculated by difference only where protein, fat, fibre, moisture and ash are present
Guaranteed-analysis protein and fat figures are minimums, so the calculated macro totals are not laboratory-measured composition.
Optional precision
Targeted support
The strongest fit leads. Additional options remain clearly secondary.
Strongest fit
01
Omega-3 (EPA + DHA)
Already recorded daily: 600 mg EPA + 300 mg DHA.
A reasonable supplement to keep on the shortlist for Nara because the dose is quantified and she is already taking it, but there is no joint diagnosis here that would justify pretending it is treating a problem.
Nara’s approach
Verify the total EPA+DHA across food and supplements, keep the dose consistent if it is well tolerated, and avoid stacking another omega-3 product without a reason.
Evidence and safety
EPA and DHA influence inflammatory signalling and have dog-specific evidence in several clinical contexts, including osteoarthritis, although that does not make them a proven longevity drug for a healthy dog.
One of the better-supported common canine supplements, with substantially stronger dog-specific evidence than most 'longevity' compounds. The strongest evidence is condition-specific rather than lifespan-specific.
Higher doses can cause gastrointestinal effects and may matter around bleeding risk or surgery; dose questions belong with Nara's veterinarian.
Measured in dogs, followed to a health outcome
Additional support
L-theanine + ashwagandha calming chew
Used about three times per week; the chew records 50 mg L-theanine, 120 mg ashwagandha and 75 mg chamomile extract.
Potentially useful because unfamiliar-dog stress is a real recorded issue, but it should support controlled exposure and training rather than replace them.
If Nara keeps using it, compare recovery time and trigger distance on similar outings so the owner can see whether it is adding anything meaningful.
Evidence and safety
The most relevant question is whether it helps Nara stay below threshold or recover faster during behaviour work, not whether a calming ingredient sounds generally healthy.
L-theanine has some canine behavioural evidence; dog-specific evidence for ashwagandha is much thinner. The combination is better treated as a possible adjunct than as the core intervention.
Combination products make attribution difficult and can interact with medications; review continued use with a veterinarian if other sedating or behaviour-active drugs are added.
Measured in dogs, as a marker
Additional support
Urolithin A
250 mg daily for about six weeks.
Interesting enough to track, but not strong enough to displace the much clearer opportunities in movement, nutrition and emotional wellbeing.
Do not escalate it simply because it is labelled a longevity supplement. Keep it secondary, record tolerance, and revisit as dog-specific evidence develops.
Evidence and safety
Urolithin A is interesting because of mitochondrial and mitophagy biology, but biological plausibility is not the same as demonstrated benefit in dogs.
Emerging and investigational for canine healthspan. Most of the excitement comes from mechanistic and non-canine evidence rather than established dog outcomes.
Long-term canine dosing and safety are not established well enough to treat this like a routine foundational supplement.
Mechanism, not yet tested in dogs
The return path
What Nara will look for next
The plan stays connected to what is recorded, what changes, and the next decision.
Now
Record the response
- Body weight and condition
The goal is to preserve leanness while activity and diet composition evolve.
Monthly - Comfort and recovery after activity
A change in next-day recovery can become visible before normal daily movement obviously declines.
Weekly - Recovery after unfamiliar-dog encounters
Shorter recovery gives the wellbeing plan an outcome that can be compared over time.
After relevant encounters
Next
Build a comparable trend
Use the same method each time so a real change is easier to distinguish from noise.
Review
In 8 weeks
At least one priority in this report calls for a check-in within eight weeks.
Decision
Continue, adjust or stop
The next decision follows the recorded response, not a prewritten outcome.
When to reassess sooner
Reassess sooner if A new symptom or safety concern appears; Body weight or body condition changes noticeably; A recommended action could not be completed.
The unknowns
What could sharpen the next decision
Only information that could materially improve a later decision is elevated here.
- The macro composition of the training treats and dental chew
- A routine CBC and chemistry panel to create a clinical comparison point
See all recorded information gaps
Missing information
These reduce confidence in parts of this report. They describe gaps in what was recorded, not shortcomings in how this dog is cared for.
How safe, settled and engaged the dog appears in everyday life.
Easy to getA physically healthy dog can still have a meaningful quality-of-life opportunity in fear, stress, sleep or enjoyment.
What it blocks: Emotional wellbeing
How to get it: Complete the five-question Emotional wellbeing module.
Would change a decision
Whether any diagnosed medical conditions are present.
Easy to getUnknown medical status gates safe advice in every other domain, including nutrition and activity.
What it blocks: Medical context, Nutrition, Activity and function, Supplements and interventions
How to get it: Answer whether your dog has any diagnosed conditions, even if details are incomplete.
Would change a decision
A muscle condition assessment.
Easy to getMuscle mass is scored separately from body fat, and low muscle mass can exist at any body condition score.
What it blocks: Muscle condition
How to get it: Run the guided muscle check over the skull, shoulders, spine and hind limbs, or ask your vet to score it.
Would change a decision
Deeper verification
Evidence and methodology
Technical provenance stays available without competing with the conclusions and actions above.
Body condition scale
Body condition score: 5 on a 9-point veterinary scale. A score of 5 is the centre of the ideal range; higher numbers indicate more body fat.
Evidence used in this report
In Labrador Retrievers fed a restricted ration for life, median lifespan was longer and chronic disease appeared later than in paired littermates fed without restriction.
Keeping a dog lean is the best-supported single thing an owner can do for healthspan, even though the underlying trial record is narrow.
What remains uncertain: The size of the effect in mixed-breed pet dogs at home is not established.
- — Single breed studied in a controlled kennel environment.
- — Restriction must be managed carefully so it does not become undernutrition.
Sources
- Kealy et al.. (2002). Effects of diet restriction on life span and age-related changes in dogs. Journal of the American Veterinary Medical Association.
In aged research beagles, a combined programme of antioxidant diet, physical exercise and cognitive training slowed measured cognitive decline relative to standard care.
Keeping an older dog physically and mentally engaged is well motivated, but the exact recipe is not established.
What remains uncertain: No component can be credited individually, and home settings differ.
- — Combined intervention, so no single component can be credited.
- — Research colony beagles rather than pet dogs at home.
Sources
- Milgram et al.. (2005). Behavioural enrichment and dietary fortification in aged dogs. Neurobiology of Aging.
In dogs with diagnosed osteoarthritis, fish-derived omega-3 supplementation improved weight-bearing and reduced inflammatory markers compared with a control diet.
Reasonable to discuss for a dog with joint disease; not established as a general healthspan intervention.
What remains uncertain: Whether supplementation helps a dog without joint disease is unknown.
- — Studied in dogs that already had osteoarthritis.
- — High intakes can affect clotting; relevance depends on the individual dog.
Sources
- Roush et al.. (2010). Multicenter practice assessment of omega-3 fatty acids in dogs with osteoarthritis. Veterinary Therapeutics.
Across randomised canine trials, glucosamine-chondroitin has shown inconsistent effects on clinical signs of osteoarthritis: some trials report improvement and others no difference from placebo.
Not something to rely on for joint disease, and not a reason to delay measures with better support.
What remains uncertain: No reliable way to predict which dogs, if any, respond.
- — Product quality and formulation vary substantially between trials.
- — Trial reporting quality is uneven.
Sources
- Vandeweerd et al.. (2012). Systematic review of nutraceuticals for clinical signs of osteoarthritis in dogs. Veterinary Journal.
Dogs with degenerative joint disease show altered activity and rest patterns, and pain management has been associated with improved rest in clinical studies.
What remains uncertain: Changes in rest have many possible causes and are not diagnostic on their own.
- — Sleep and rest changes are non-specific.
- — Owner-reported measures carry recall effects.
Sources
- Gruen et al.. (2019). Sleep and activity patterns in dogs with degenerative joint disease pain. Scientific Reports.
What Nara reviewed
What we looked at
Every area of health Nara reviews, including the ones with nothing yet recorded. What is missing is information too.
Body condition
Looking goodNara's body condition score is 5/9, within the ideal range of 4-5.
- Body condition score
- 5/9
A score of 5/9 reflects an ideal amount of body fat. This says nothing about muscle mass, which is tracked as its own domain.
Muscle condition
Not enough recorded yetNo muscle condition assessment has been recorded for Nara.
Nutrition
Worth watchingNothing in the recorded diet raises a nutritional concern; the estimate could be sharpened.
- Estimated daily calorie intake
- 873.5 kcal/day
This is recorded intake, not an estimate of daily energy needs.
What would sharpen this: Weighing a representative portion of the estimated component.
Activity and function
Worth watchingActivity information has been recorded for Nara.
- Post-exercise stiffness
- none
- Diagnosed joint or orthopaedic condition
- no
- Injury or surgery affecting movement
- none
Activity information has been recorded for Nara.
What would sharpen this: Explicit confirmation of no mobility concerns, or a description of any observed.
Preventive and dental care
Looking goodPreventive and dental care appears reasonably current.
Preventive and dental care appears reasonably current.
Supplements and interventions
Worth watchingA Nara review is not yet available for Ashwagandha (KSM-66). This is noted rather than assessed.
- Fish oil / omega-3
- 5mL
- Urolithin A
- 250mg
- Ashwagandha (KSM-66)
- 120mg
A Nara review is not yet available for Ashwagandha (KSM-66). This is noted rather than assessed.
Medical context
Not enough recorded yetWhether Nara has any diagnosed medical conditions has not been recorded.
Emotional wellbeing
Not enough recorded yetEmotional wellbeing has not yet been assessed for Nara.
Supplements you recorded
Supplements you are already giving
Every product recorded appears here — 3 in total, 2 matched to reviewed evidence. Nothing is dropped for lack of a match, and no product borrows another product's evidence.
Fish oil / omega-3
Nordic Naturals · oil · currently given
5 mL per serving — about 5 mL per day — daily.
Matched to Marine omega-3 fatty acids, EPA and DHA.
Nara completed this assessment using the recorded product information and reviewed evidence.
EPA and DHA have direct canine evidence for selected clinical uses, especially osteoarthritis. Value depends on the dog, diet, goal, confirmed EPA and DHA dose and product quality.
Dogs cannot efficiently convert plant-derived ALA to active EPA and DHA.
established · canine surrogate
High-dose EPA improves joint mobility and force-plate peak vertical force in canine osteoarthritis.
established · direct canine outcome
DHA supports neural membrane fluidity, synaptic plasticity, and cognitive healthspan.
supported · direct canine outcome
Total fish-oil milligrams or a generic omega-3 label do not establish an effective EPA or DHA intake.
Veterinary guidance may be appropriate when pancreatitis or a strict low-fat diet is relevant. Veterinary guidance may be appropriate when bleeding risk, anticoagulants or upcoming surgery is relevant. Keep note of storage and when the bottle was opened, since oils lose quality over time. Capture EPA and DHA separately, include oil calories, and record product form, storage and relevant medical context.
Evidence reviewed (5 sources)
Evidence reviewed at dossier level: the sources below were reviewed together for this intervention, not matched one-to-one to each statement.
- Bauer JE. Therapeutic use of fish-derived omega-3 fatty acids in companion animals. Journal of the American Veterinary Medical Association. 2011;239(11):1441-1451.
- Roush JK, Cross AR, Renberg WC, et al. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with osteoarthritis. Journal of the American Veterinary Medical Association. 2010;236(1):67-73.
- Canine Arthritis Resources and Education (CARE). Overview of Omega-3 Fatty Acids for Osteoarthritis Dosing and Mechanics in Dogs. Veterinary Clinical Guidelines. 2024–2026.
- Hadley KB, Bauer J, et al. The Essentiality of Dietary Eicosapentaenoic Acid and Docosahexaenoic Acid in Canine and Feline Nutrition: A Comparative Review. Veterinary Clinics of North America: Small Animal Practice. 2023;53(4):811-828.
- National Research Council (NRC). Nutrient Requirements of Dogs and Cats: Polyunsaturated Fatty Acid Caps and Lipid Peroxidation Safety Parameters. National Academies Press.
Urolithin A
Timeline · powder · currently given
250 mg per serving — about 250 mg per day — daily.
Matched to Urolithin A.
Nara completed this assessment using the recorded product information and reviewed evidence.
Urolithin A activates mitochondrial quality-control pathways and has human and animal evidence related to mitochondrial and muscle biology. Direct canine outcome evidence is limited.
Oral Urolithin A supplementation carries a wide safety margin in dogs.
supported · canine safety or pk
Urolithin A triggers PINK1/Parkin-mediated mitophagy and mitochondrial renewal across mammalian species. Evidence is indirect, limited, or context-specific in dogs.
established · mixed or indirect
Feeding dietary precursors (pomegranate/ellagitannins) is an unreliable substitute for direct Urolithin A. Evidence is indirect, limited, or context-specific in dogs.
supported · mixed or indirect
Mitophagy activation does not prove improved canine mobility, cognition, healthspan or lifespan.
Keep direct Urolithin A separate from pomegranate, ellagic acid and other precursor foods.
Evidence reviewed (5 sources)
Evidence reviewed at dossier level: the sources below were reviewed together for this intervention, not matched one-to-one to each statement.
- Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Medicine. 2019;25(9):1382-1389.
- Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633.
- Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022;5(1):e2142031.
- Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016;22(8):879-888.
- D'Amico D, Andreux PA, Valdés P, et al. Mitophagy Activation by Urolithin A to Target Muscle Aging. Frontiers in Nutrition / PMC. 2023;10:10791945.
Ashwagandha (KSM-66)
chew · currently given
120 mg per serving — about 51.43 mg per day — 3 times per week.
Nara recorded this product exactly as entered. It is not matched to a reviewed intervention, so it could not be assessed.
What would sharpen this
- The brand and product name on the label, so the product can be matched to a reviewed intervention.
Evidence package 0.1.1 (schema 1.0.1).
Report details
Saved 1/15/2026 · Generated 2026-01-15T09:00:00.000Z · Schema v1 · Content v43 · partial generation